Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

Wells Fargo analyst Evan Stampler maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $5.5 to $6.5.